Stroke drug study halted early after testing new dosing
Disease control
Terminated
This study tested a new way of giving the drug MCI-186 to people who had a recent ischemic stroke. The goal was to see if a different dosing schedule could improve recovery better than the standard twice-daily regimen. Only 17 people took part before the study was stopped early.
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 14, 2026 12:02 UTC